NCT07326813

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis.

A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis.

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 477 (estimated)
• Sponsor: InventisBio Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	D-2570 Tablet	D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain
DRUG	BMS-986165 Tablet	BMS-986165 is a novel inhibitor targeting TYK2
DRUG	Placebo	A placebo refers to a tablet that has no therapeutic effect on medication

Timeline

• Start date: 2026-01-13
• Primary completion: 2027-04-12
• Completion: 2027-08-03
• First posted: 2026-01-08
• Last updated: 2026-01-08

Locations

1 site across 1 country: China